News

Back General News Investor Updates

Emyria Company Update – December 2022

Emyria Company Update – December 2022

Emyria has released its latest Company Update, highlighting our:

  • Clinical Focus
  • Investment Highlights,
  • Vision
  • Advanced cannabinoid development
  • Our Real World Data
  • Clinical Program – Including Emyria’sUltra-Pure cannabinoid delivery platform
  • Preclinical Pipeline
  • Clinical opportunities for MDMA analogues
  • Corporate Details & IP
  • Leadership and Advisory team
  • Patent portfolio
  • Corporate structure

You can read the complete December 2022 Company Overview here

Call 08 6559 2800Contact